AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that Company management will participate in the private company tracks of two upcoming investor conferences.
Piper Sandler Biopharma Symposium
1x1 Meetings: Wednesday, April 15, 2026
Location: Boston, MA
UBS Private Biotech Summit
1x1 Meetings: Monday, May 18, 2026
Location: New York, NY
About Ollin Biosciences
Established in 2023, Ollin BiosciencesTM is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology. For more information, please visit us at www.ollin.bio and follow us on LinkedIn and X.
Contacts
Media & Investors:
Katie Engleman
1AB
katie@1abmedia.com
